Archive position — measured, not model output
0 likes on Devpost
2,264 of the 7,856 archived projects have more likes, and 5,592 share exactly 0 — so this project's #2,661 place in the like-ranked listing is a tie-break inside that group, not a ranking.
Projects (log scale)
Likes on Devpost. ▲ marks this project's group.
Show the figures
| Likes | Projects | Share of archive |
|---|---|---|
| 0 | 5,592 | 71.2% |
| 1 | 1,758 | 22.4% |
| 2 | 285 | 3.6% |
| 3–4 | 132 | 1.7% |
| 5–9 | 75 | 1.0% |
| 10+ | 14 | 0.2% |
Executive Summary
What the company appears to be
Antibody Labmate is a self-reported computational workflow tool for antibody design, intended to streamline the process from CDR inputs to ranked candidates and interpretable reports. It is described as under active development, with three execution modes: Replay (for demos), Live Local (on user’s machine), and Live Remote (via remote worker). The project is built using Python, BioPython, Pydantic, Streamlit, and various bioinformatics tools.
What changed
The author states that the tool was developed as part of a hackathon submission. It is not clear whether this represents an initial prototype or a product in development. No prior version or evolution from earlier work is described.
Single most important open question
Is there any evidence of real-world use, customer feedback, or traction beyond the author’s own description?
What The Product Actually Is
The description states that Antibody Labmate is a computational antibody-design workflow. It takes six IMGT-defined CDR sequences and an antigen structure as inputs.
It performs:
- Input validation
- Candidate VH/VL sequence generation
- Candidate structure prediction
- Protein-protein docking
- Interface residue analysis
- Produces a ranked candidate table and offline HTML report
Execution modes include:
- Replay: Stable, labeled replay of verified fixtures for demos/testing.
- Live Local: Real computation on the user’s own machine after checks pass.
- Live Remote: Real computation through an authorized remote worker using the same artifact schema.
The system is built around a shared artifact contract that records normalized inputs, hashes, tool versions, model versions, parameters, chain mappings, stage status, and output artifacts in a manifest.
Evidence
- The description states this is a workflow for antibody design.
- It lists specific steps: input validation, candidate generation, structure prediction, docking, analysis, reporting.
- Execution modes are defined with clear distinctions between replay and live computation.
- Technical stack includes Python, Pydantic, Streamlit, BioPython, Jinja2, etc.
Inference The tool is designed to be modular and reproducible, using adapters for different stages like generation, folding, docking, and visualization.
Positioning & Claim Evolution
The author positions Antibody Labmate as a transparent, reproducible, and interpretable workflow that simplifies the process of moving from antibody CDR inputs to computational candidates and reports.
It aims to:
- Reduce reliance on multiple tools
- Improve interpretability of outputs
- Make workflows more demonstrable and easier to share
The project is described as being built with a focus on reproducibility, scientific honesty, and clear labeling of replayed vs. live results.
Evidence
- The tagline: “A transparent CDR-to-docking workflow that turns antibody CDR inputs and antigen structures into ranked computational candidates and an interpretable HTML report.”
- The write-up emphasizes transparency, reproducibility, and honesty in scientific computation.
- The project is framed as solving a problem in current antibody design workflows.
Inference The positioning reflects a shift from fragmented tools to integrated, explainable outputs. However, no evidence of market positioning or competitive differentiation beyond the author’s own claims.
Target Customer & ICP
The description does not clearly define a target customer or ideal customer profile (ICP). It is implied that users would be involved in antibody engineering, likely researchers or scientists working with computational biology or biopharma.
It is also implied that users might be interested in:
- Reproducible workflows
- Transparent outputs
- Interpretable reports
Evidence
- The tool is built for antibody design workflows.
- It takes CDR sequences and antigen structures as inputs — typical of bioinformatics or computational biology use cases.
- No explicit mention of end-user personas, roles, or industries.
Inference The likely users are scientists or engineers in antibody engineering or computational biology. However, no evidence supports a defined ICP beyond implied usage.
Business Model & Pricing Evidence
There is no evidence of any business model or pricing structure.
Evidence
- The description does not mention revenue, pricing, licensing, subscriptions, or monetization.
- No information about customers, sales cycles, or commercial relationships.
Inference If the tool is intended for commercial use, it has not been described as such. It appears to be a prototype or open-source project submitted for a hackathon.
Technical & Delivery Signals
The system is built using:
- Python
- BioPython
- Pydantic (for data models)
- Streamlit (for UI)
- Jinja2 (for HTML reporting)
- Optional PyMOL rendering
- Adapters for candidate generation, folding, docking, and visualization
It uses a shared artifact contract to track inputs, versions, hashes, parameters, and outputs.
Execution modes:
- Replay: stable, demo-ready
- Live Local: requires local tooling and resources
- Live Remote: uses remote worker with same schema
Evidence
- The project lists specific technologies used.
- It describes modular design using adapters.
- It defines execution modes and their constraints.
- It mentions the need for tool and resource checks before live computation.
Inference The system is designed to be modular, reproducible, and extensible. However, no evidence of deployment, scalability, or production readiness.
Traction & Maturity Signals
There is no evidence of traction, adoption, or maturity beyond the author’s own description.
Evidence
- The project was submitted as a hackathon entry.
- No mention of users, customers, or real-world application.
- No data on usage, performance, or feedback.
- No indication of revenue, funding, or growth metrics.
Inference The tool is in early development. It may be an MVP or prototype, with no evidence of market validation or product-market fit.
Competitive Context
There is no evidence of competitive analysis or awareness of existing tools in the space.
Evidence
- No mention of competitors.
- No reference to existing platforms for antibody design or computational biology workflows.
- No indication of how Antibody Labmate compares to other tools.
Inference The project does not appear to be positioned against a known competitive landscape. It may be an original idea or a novel approach, but this is unverified.
Key Risks & Red Flags
Key risks and red flags include:
- Lack of traction: No evidence of real-world use or adoption.
- Unproven commercial viability: No business model or pricing structure described.
- Technical complexity without validation: The tool involves complex bioinformatics, but no evidence of successful deployment or performance.
- Replay vs. live computation: Live modes are not yet enabled, suggesting incomplete development.
- Scientific honesty claims: The description emphasizes scientific honesty and limitations, which is good, but also suggests that the tool may not yet be fully functional for real use.
Evidence
- The project is described as under active development.
- Live capabilities remain unavailable until dependencies are resolved.
- No evidence of product-market fit or customer feedback.
Inference The tool is in early stages and has not been validated in practice. It may be a promising concept but lacks real-world validation.
Diligence Questions To Ask The Founders
- What is the current status of Live Local and Live Remote modes? Are they functional or still under development?
- How does the tool handle licensing and compliance for docking software, especially in public or remote deployments?
- Has the CDR-only generation adapter been validated experimentally?
- Is there any internal testing or feedback from users in antibody engineering or computational biology?
- What is the roadmap for commercialization or monetization?
- How does the tool ensure reproducibility when inputs are changed, and how is this tracked in the manifest?
- Are there plans to integrate with existing platforms or tools in the antibody design space?
Investment/Partnership Verdict
Not evidenced
There is no evidence of revenue, customers, traction, or commercial viability beyond the author’s own description. The project appears to be a prototype or hackathon submission, not a product in active use or development with clear market demand.
The tool is described as under active development, and live capabilities are not yet enabled. No indication of funding, partnerships, or business model exists.
Confidence Low This analysis is based entirely on self-reported information, with no independent verification or evidence of traction, adoption, or commercialization.
Source
Submitted to the OpenAI 2026 hackathon on Devpost. Project home on DevPost.
The analysis above was generated by a language model from the project's own one-line description. It is not independent research and contains no verified traction, revenue or customer data.